Giovanni Melillo
AstraZeneca (Brazil)(BR)AstraZeneca (United States)(US)
Publications by Year
Research Areas
Cancer, Hypoxia, and Metabolism, Cancer Immunotherapy and Biomarkers, Cancer therapeutics and mechanisms, Angiogenesis and VEGF in Cancer, Neuroblastoma Research and Treatments
Most-Cited Works
- → Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer(2017)4,427 cited
- → Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC(2018)2,750 cited
- → Regulation of the Chemokine Receptor CXCR4 by Hypoxia(2003)824 cited
- → A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter.(1995)631 cited
- → Echinomycin, a Small-Molecule Inhibitor of Hypoxia-Inducible Factor-1 DNA-Binding Activity(2005)508 cited
- Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway.(2002)
- → Human Monocytes Undergo Functional Re-programming during Sepsis Mediated by Hypoxia-Inducible Factor-1α